Lai P K
Transplantation. 1985 Jun;39(6):638-43. doi: 10.1097/00007890-198506000-00013.
Two populations of class-I-restricted CTL are generated from BDF1 mice against multiple minor-HA when BALB.B cells carrying multiple minor-HA are used as immunogen, whereas one population of Db-restricted CTL is generated when H-25.3 antigen on B6.C-H-25c cells is used as antigen. CTL generated against H-25.3 antigen on B6.C-H-25c cells are cytolytic to B6.C-H-25c and BALB.B targets, whereas CTL generated in the same manner with multiple minor-HA on BALB.B cells kill BALB.B targets only. This must be an instance of antigen competition, because H-25.3 antigen is immunostimulatory when used on its own, but not when accompanied by other minor-HA. This competition effect is not an artefact seen during the generation of CTL in MLC cultures in vitro, because it is also seen during the generation of CTL in vivo. We have not identified the immunodominant antigen(s) on BALB.B cells. We have studied this form of antigen competition in some detail. First, BDF1 spleen primed in vivo to multiple minor-HA on BALB.B cells do not respond in vitro to restimulation by H-25.3 antigen, suggesting that antigen competition is not mediated by suppressor cells, but that BALB.B cells do not prime BDF1 spleen cells against H-25.3 antigen in vivo. Second, BDF1 spleen cells primed to the same multiple minor-HA carried on F1(BALB/c X B6.C-H-25c) cells respond to restimulation by H-25.3 antigen in vitro. Third, BDF1 spleen cells primed in vivo to H-25.3 antigen on B6.C-H-25c cells do not respond in vitro to restimulation by multiple minor-HA on BALB.B cells, but they do respond to F1(BALB/c X B6.C-H-25c) cells that carry the same multiple minor-HA as BALB.B cells, and generate Db-restricted anti-H-25.3 CTL. Fourth, BDF1 spleen cells primed in vivo and boosted in vitro with B6.C-H-25c cells readily develop CTL to H-25.3 antigen, whereas when the BDF1 mice are exposed to H-25.3 antigen in vivo by repeated footpad injections of B6.C-H-25c cells, CTL to H-25.3 antigen do not develop. However, anti-H-25.3 CTL do develop after H-25.3 antigen-bearing B6.C-H-25c cells and antigen-specific Th cells are injected into preprimed BDF1 mice. These results are discussed with respect to possible mechanisms of antigen competition.
当将携带多种次要组织相容性抗原(minor - HA)的BALB.B细胞用作免疫原时,BDF1小鼠会产生两类针对多种次要HA的I类分子限制性细胞毒性T淋巴细胞(CTL);而当将B6.C - H - 25c细胞上的H - 25.3抗原用作抗原时,会产生一类Db限制性CTL。针对B6.C - H - 25c细胞上H - 25.3抗原产生的CTL对B6.C - H - 25c细胞和BALB.B靶细胞具有细胞溶解作用,而以同样方式利用BALB.B细胞上的多种次要HA产生的CTL仅杀伤BALB.B靶细胞。这肯定是抗原竞争的一个实例,因为H - 25.3抗原单独使用时具有免疫刺激作用,但与其他次要HA同时存在时则不然。这种竞争效应并非在体外混合淋巴细胞培养(MLC)中产生CTL的过程中出现的人为现象,因为在体内产生CTL的过程中也能看到这种现象。我们尚未确定BALB.B细胞上的免疫显性抗原。我们已经对这种抗原竞争形式进行了较为详细的研究。首先,在体内用BALB.B细胞上的多种次要HA致敏的BDF1脾细胞,在体外对H - 25.3抗原的再刺激无反应,这表明抗原竞争不是由抑制性细胞介导的,而是BALB.B细胞在体内未能使BDF1脾细胞针对H - 25.3抗原致敏。其次,用F1(BALB/c×B6.C - H - 25c)细胞上携带的相同多种次要HA致敏的BDF1脾细胞,在体外对H - 25.3抗原的再刺激有反应。第三,在体内用B6.C - H - 25c细胞上的H - 25.3抗原致敏的BDF1脾细胞,在体外对BALB.B细胞上多种次要HA的再刺激无反应,但它们对携带与BALB.B细胞相同多种次要HA的F1(BALB/c×B6.C - H - 25c)细胞有反应,并产生Db限制性抗H - 25.3 CTL。第四,在体内致敏并用B6.C - H - 25c细胞在体外增强的BDF1脾细胞很容易产生针对H - 25.3抗原的CTL,而当通过对BDF1小鼠重复足垫注射B6.C - H - 25c细胞使其在体内接触H - 25.3抗原时,针对H - 25.3抗原的CTL却无法产生。然而,在将携带H - 25.3抗原的B6.C - H - 25c细胞和抗原特异性Th细胞注射到预先致敏的BDF1小鼠体内后,抗H - 就可能的抗原竞争机制对这些结果进行了讨论。